Drug intelligence / Profile preview

ART5900

Development stage: Preclinical
Lead developer: Arialys Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ART5900 is a preclinical-stage monoclonal antibody therapeutic being developed by Arialys Therapeutics for the treatment of anti-N-methyl-D-aspartate receptor (anti-NMDAR) autoimmunity. The drug utilizes blood-brain barrier (BBB) penetrant technology to deliver the monoclonal antibody into the central nervous system, where it is designed to target the NMDA receptor and block the pathogenic effects of autoantibodies associated with autoimmune neuropsychiatric disorders.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on ART5900.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART5900.

Explore the full profile